Home/Pipeline/Lu AG06466

Lu AG06466

Parkinson's Disease Psychosis

Phase 2Active

Key Facts

Indication
Parkinson's Disease Psychosis
Phase
Phase 2
Status
Active
Company

About Lundbeck

Lundbeck is a Danish, publicly-traded biopharmaceutical leader with a century-long legacy, exclusively focused on central nervous system (CNS) disorders. Its strategy as a 'Focused Innovator' leverages deep, accumulated expertise in neuroscience to navigate the complexities of CNS drug development and commercialization. The company has built a significant global commercial footprint, particularly in the U.S., and maintains a robust pipeline aimed at addressing high-unmet-need conditions in psychiatry, neurology, and neuro-rare diseases, underpinned by a strong financial position with a market valuation of approximately $39 billion.

View full company profile

About Lundbeck

Lundbeck is a Danish, publicly-traded biopharmaceutical leader with a century-long legacy, exclusively focused on central nervous system (CNS) disorders. Its strategy as a 'Focused Innovator' leverages deep, accumulated expertise in neuroscience to navigate the complexities of CNS drug development and commercialization. The company has built a significant global commercial footprint, particularly in the U.S., and maintains a robust pipeline aimed at addressing high-unmet-need conditions in psychiatry, neurology, and neuro-rare diseases, underpinned by a strong financial position with a market valuation of approximately $39 billion.

View full company profile

Other Parkinson's Disease Psychosis Drugs

DrugCompanyPhase
MIN-301Minerva NeurosciencesPreclinical / Early Clinical